<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02186002</url>
  </required_header>
  <id_info>
    <org_study_id>AC-071-101</org_study_id>
    <nct_id>NCT02186002</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)</brief_title>
  <official_title>Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose, With Nested Cross-over for Food Effect, to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the safety and tolerability of ACT-451840&#xD;
      in healthy male subjects.Secondary objectives were : to investigate the pharmacokinetics (PK)&#xD;
      of ACT-451840; to investigate the effect of food on the PK of ACT-451840; to evaluate the&#xD;
      urinary excretion of ACT-451840 and to investigate the antimalarial activity of ACT-451840.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic blood pressure from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in diastolic blood pressure from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pulse rate from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body weight from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>Body weight will be measured using the same weighing scale for all subjects and throughout the study. The weighing scale should have a precision of at least 0.5 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>Heart rate will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PQ/PR interval from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>PQ/PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QRS interval from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>QRS interval (time interval from the beginning of the Q wave to the end of the S wave) will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QTc interval (time interval from beginning of the Q wave until end of the T wave) according to Fridericia's correction (QTcF interval) from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>QTcF interval will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. The QTcF interval is the QTc interval corrected for heart rate with Fridericia's formula (QTcB = QT/RR^0.33 where RR is 60/heart rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QTc interval (time interval from beginning of the Q wave until end of the T wave) according to Bazett's correction (QTcB interval) from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>QTcB interval will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. The QTcB interval is the QTc interval corrected for heart rate with Bazett's formula (QTcB = QT/RR^0.5 where RR is 60/heart rate).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent electrocardiogram abnormalities from baseline up to end of study</measure>
    <time_frame>4 days</time_frame>
    <description>Treatment-emergent electrocardiogram abnormalities will be identified using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.&#xD;
Cmax will be calculated on the basis of the blood sampling time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.&#xD;
tmax will be calculated on the basis of the blood sampling time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.&#xD;
AUC(0-t) will be calculated as the area under the plasma concentration-time profile from time zero to time t of the last measured concentration above the limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.&#xD;
AUC(0-infinity) will be calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half life (t1/2) of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.&#xD;
t1/2 will be calculated on the basis of the blood sampling time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose proportionality of single doses of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.&#xD;
Dose proportionality will be explored by the power model as described by Gough et al [1995]. The power model will be applied to the loge AUC0-∞ and Cmax data. A point estimate and 90% Confidence Interval (CI) will be produced for the population mean slope. Approximate dose proportionality will be concluded if the 90% CI for the slope is completely contained in the range (1+log(0.5))/log(r), 1+log(2)/log(r) where r = high dose/low dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of administered ACT-451840 excreted unchanged in urine</measure>
    <time_frame>4 days</time_frame>
    <description>A baseline urine sample will be collected from each subject in the selected dose group after admission on Day -1. On Day 1, subjects will be instructed to empty their bladder immediately prior to study drug intake. Thereafter, all urine produced will be collected during the 4 days following study drug intake until the morning of Day 5. On Day 1, urine will be collected at three consecutive 8-hour intervals, from 0-8 hours, 8-16 hours, and 16-24 hours. On Days 2, 3, and 4 urine will be collected in 24-hours intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-malarial half-maximal inhibitory concentration (IC50) of ACT-451840</measure>
    <time_frame>4 days</time_frame>
    <description>Blood (2.5 mL) will be collected by direct venipuncture or via an intravenous catheter placed in an antecubital vein in the arm into 3.5 mL vacutainer serum separation tubes. The anti-malarial IC50 of ACT-451840 will be determined using a bioassay and ACT-451840 IC50 concentrations will be estimated based on the measured antimalarial activity.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-451840 10 mg</intervention_name>
    <description>ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-451840 50 mg</intervention_name>
    <description>ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-451840 200 mg</intervention_name>
    <description>ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-451840 500 mg</intervention_name>
    <description>ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-451840 1000 mg</intervention_name>
    <description>ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-451840 (Dose to be determined)</intervention_name>
    <description>ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in the local language prior to any study-mandated procedure.&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse&#xD;
             rate 45-90 beats per minute (inclusive), measured on the dominant arm, after 5 min in&#xD;
             the supine position at screening.&#xD;
&#xD;
          -  12-lead electrocardiogram without clinically relevant abnormalities, measured after 5&#xD;
             min in the supine position at screening.&#xD;
&#xD;
          -  Hematology, coagulation, clinical chemistry, and urinalysis test results not deviating&#xD;
             from the normal range to a clinically relevant extent at screening.&#xD;
&#xD;
          -  No clinically significant findings on the physical examination at screening.&#xD;
&#xD;
          -  Negative results from urine drug screen at screening.&#xD;
&#xD;
          -  Ability to communicate well with the investigator, in the local language, and to&#xD;
             understand and comply with the requirements of the study.&#xD;
&#xD;
          -  Subject covered by Health Insurance system and/or in compliance with the&#xD;
             recommendations of the National Law in force relating to biomedical research.&#xD;
&#xD;
          -  If the subject's partner could become pregnant, reliable methods of contraception must&#xD;
             be used from the time of the first administration of study medication until 3 months&#xD;
             following administration of the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s).&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition which might interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the study drug.&#xD;
&#xD;
          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal&#xD;
             reactions.&#xD;
&#xD;
          -  Documented history of chronic liver or gall bladder disease.&#xD;
&#xD;
          -  Documented history of hemolytic anemia.&#xD;
&#xD;
          -  Veins unsuitable for intravenous puncture on either arm (e.g., veins that are&#xD;
             difficult to locate, access, or puncture, veins with a tendency to rupture during or&#xD;
             after puncture).&#xD;
&#xD;
          -  Previous exposure to the study medication.&#xD;
&#xD;
          -  Treatment with another investigational drug within 3 months prior to screening or&#xD;
             participation in more than four investigational drug studies within the 12 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Subject in the exclusion period of a previous clinical study.&#xD;
&#xD;
          -  Subject who had received more than 4,500 Euros as indemnities for his participation in&#xD;
             a biomedical research within the 12 last months, including the indemnities for the&#xD;
             present study.&#xD;
&#xD;
          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period&#xD;
             prior to screening.&#xD;
&#xD;
          -  Excessive caffeine consumption, defined as 800 mg or more per day at screening.&#xD;
&#xD;
          -  Smoking within 3 months prior to screening and inability to refrain from smoking&#xD;
             during the course of the study.&#xD;
&#xD;
          -  Previous treatment with any prescribed or over-the-counter medications (including&#xD;
             herbal medicines such as St. John's Wort) within 2 weeks prior to first study drug&#xD;
             administration.&#xD;
&#xD;
          -  Loss of 250 mL or more of blood within 3 months prior to screening.&#xD;
&#xD;
          -  Positive results from the hepatitis (hepatitis B and C) serology, except for&#xD;
             vaccinated subjects.&#xD;
&#xD;
          -  Positive results from human immunodeficiency virus serology at screening.&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OPTIMED Clinical Research</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACT-451840</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02186002
org study id: AC-071-101
nct id: NCT02186002
lead sponsor: 
has dmc: No
The primary objective of the study was to evaluate the safety and tolerability of ACT-451840
      in healthy male subjects.Secondary objectives were : to investigate the pharmacokinetics (PK)
      of ACT-451840; to investigate the effect of food on the PK of ACT-451840; to evaluate the
      urinary excretion of ACT-451840 and to investigate the antimalarial activity of ACT-451840.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: Triple (Participant, Investigator, Outcomes Assessor)
measure: Change in systolic blood pressure from baseline up to end of study
time frame: 4 days
description: Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.
measure: Change in diastolic blood pressure from baseline up to end of study
time frame: 4 days
description: Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.
measure: Change in pulse rate from baseline up to end of study
time frame: 4 days
description: Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the dominant/same arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.
measure: Change in body weight from baseline up to end of study
time frame: 4 days
description: Body weight will be measured using the same weighing scale for all subjects and throughout the study. The weighing scale should have a precision of at least 0.5 kg.
measure: Change in heart rate from baseline up to end of study
time frame: 4 days
description: Heart rate will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.
measure: Change in PQ/PR interval from baseline up to end of study
time frame: 4 days
description: PQ/PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.
measure: Change in QRS interval from baseline up to end of study
time frame: 4 days
description: QRS interval (time interval from the beginning of the Q wave to the end of the S wave) will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.
measure: Change in QTc interval (time interval from beginning of the Q wave until end of the T wave) according to Fridericia's correction (QTcF interval) from baseline up to end of study
time frame: 4 days
description: QTcF interval will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. The QTcF interval is the QTc interval corrected for heart rate with Fridericia's formula (QTcB = QT/RR^0.33 where RR is 60/heart rate)
measure: Change in QTc interval (time interval from beginning of the Q wave until end of the T wave) according to Bazett's correction (QTcB interval) from baseline up to end of study
time frame: 4 days
description: QTcB interval will be measured using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing. The QTcB interval is the QTc interval corrected for heart rate with Bazett's formula (QTcB = QT/RR^0.5 where RR is 60/heart rate).
measure: Number of treatment-emergent electrocardiogram abnormalities from baseline up to end of study
time frame: 4 days
description: Treatment-emergent electrocardiogram abnormalities will be identified using a standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. Electrocardiograms will be performed immediately prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours post dosing.
measure: Maximum plasma concentration (Cmax) of ACT-451840
time frame: 4 days
description: Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.
Cmax will be calculated on the basis of the blood sampling time points.
measure: Time to maximum plasma concentration (tmax) of ACT-451840
time frame: 4 days
description: Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.
tmax will be calculated on the basis of the blood sampling time points.
measure: Area under the plasma concentration-time curve (AUC(0-t)) of ACT-451840
time frame: 4 days
description: Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.
AUC(0-t) will be calculated as the area under the plasma concentration-time profile from time zero to time t of the last measured concentration above the limit of quantification.
measure: Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-451840
time frame: 4 days
description: Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.
AUC(0-infinity) will be calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase.
measure: Plasma half life (t1/2) of ACT-451840
time frame: 4 days
description: Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.
t1/2 will be calculated on the basis of the blood sampling time points.
measure: Dose proportionality of single doses of ACT-451840
time frame: 4 days
description: Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-451840 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, and 96 hours after dosing.
Dose proportionality will be explored by the power model as described by Gough et al [1995]. The power model will be applied to the loge AUC0-∞ and Cmax data. A point estimate and 90% Confidence Interval (CI) will be produced for the population mean slope. Approximate dose proportionality will be concluded if the 90% CI for the slope is completely contained in the range (1+log(0.5))/log(r), 1+log(2)/log(r) where r = high dose/low dose.
measure: Percentage of administered ACT-451840 excreted unchanged in urine
time frame: 4 days
description: A baseline urine sample will be collected from each subject in the selected dose group after admission on Day -1. On Day 1, subjects will be instructed to empty their bladder immediately prior to study drug intake. Thereafter, all urine produced will be collected during the 4 days following study drug intake until the morning of Day 5. On Day 1, urine will be collected at three consecutive 8-hour intervals, from 0-8 hours, 8-16 hours, and 16-24 hours. On Days 2, 3, and 4 urine will be collected in 24-hours intervals.
measure: Anti-malarial half-maximal inhibitory concentration (IC50) of ACT-451840
time frame: 4 days
description: Blood (2.5 mL) will be collected by direct venipuncture or via an intravenous catheter placed in an antecubital vein in the arm into 3.5 mL vacutainer serum separation tubes. The anti-malarial IC50 of ACT-451840 will be determined using a bioassay and ACT-451840 IC50 concentrations will be estimated based on the measured antimalarial activity.
arm group label: Group 1
arm group type: Experimental
description: A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
arm group label: Group 2
arm group type: Experimental
description: A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
arm group label: Group 3
arm group type: Experimental
description: A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
arm group label: Group 4
arm group type: Experimental
description: A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
arm group label: Group 5
arm group type: Experimental
description: A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
arm group label: Group 6
arm group type: Experimental
description: A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
intervention type: Drug
intervention name: ACT-451840 10 mg
description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
arm group label: Group 1
intervention type: Drug
intervention name: ACT-451840 50 mg
description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
arm group label: Group 2
intervention type: Drug
intervention name: ACT-451840 200 mg
description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
arm group label: Group 3
intervention type: Drug
intervention name: ACT-451840 500 mg
description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
arm group label: Group 4
intervention type: Drug
intervention name: ACT-451840 1000 mg
description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
arm group label: Group 5
intervention type: Drug
intervention name: ACT-451840 (Dose to be determined)
description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
arm group label: Group 6
intervention type: Drug
intervention name: Placebo
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
arm group label: Group 4
arm group label: Group 5
arm group label: Group 6
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 45 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Clinical Trials
role: Study Director
affiliation: Idorsia Pharmaceuticals Ltd.
facility: 
country: France
responsible party type: Sponsor